Postsurgical Treatment of Early-stage Breast Cancer With Electronic Brachytherapy: Outcomes and Health-related Quality of Life at 1 Year
Menée sur 69 patientes atteintes d'un carcinome canalaire invasif ou in situ de stade précoce et traitées par tumorectomie (âge : 50 ans ou plus), cette étude multicentrique évalue, du point de vue du taux de récidive, de la nature et de la gravité des événements indésirables, les résultats cliniques associés à une brachythérapie électronique ainsi que la qualité de vie des patientes un an après l'opération
Objectives: This multicenter registry followed up patients with early-stage breast cancer treated with breast-conserving surgery and electronic brachytherapy (EBT). This report provides 1- and 2-year updates to the initial publication. Methods: Patients were of age 50 years or more with invasive carcinoma or ductal carcinoma in situ, tumor size <=3 cm, and negative surgical margins. After lumpectomy, patients received EBT in 10 fractions over 5 days (34 Gy total). Results: Of the 69 patients enrolled, 62 were evaluated at 1 year and 20 patients at 2 years after treatment. At 1 year, 28 (45.2%) patients reported adverse events that were possibly, probably, or definitely related to treatment. Most (90%) were grade 1: manageable and typical of radiation therapy. Four events were grade 2: induration/firmness (2), field contracture (1), and seroma (1). One event was grade 3: a draining fistula at the lumpectomy site due to residual effects of a breast infection at 1 month. No recurrences have been reported. Cosmetic ratings were excellent or good in 93.4% of patients at 1 year. Most patients (69%) were energetic most or all of the time. Most patients (69% to 98%) were not affected by individual symptoms of breast disease at 1 year. Generally patients who had an adverse event did not report the corresponding symptom on the quality-of-life questionnaire. Conclusions: This registry followed up patients with early-stage breast cancer at 1 and 2 years after breast-conserving surgery and EBT. No recurrences have been reported, and adverse effects were acceptable. (C) 2012 Lippincott Williams & Wilkins, Inc.